Blackrock Neurotech is a privately-held neurotechnology company headquartered in Salt Lake City, Utah, and is widely recognized as the global leader in implantable brain-computer interface (BCI) technology. Founded in 2008 as a spinout from the University of Utah, the company has built over 15 years of continuous clinical experience with its flagship Utah Array, making it the most clinically validated invasive BCI technology in the world. Blackrock went through a rebranding from "Blackrock Microsystems" to "Blackrock Neurotech" in 2021 to reflect its strategic focus on clinical neuroprosthetic applications.
The company employs approximately 150 people across its Salt Lake City headquarters and maintains offices in San Francisco and Boston. Blackrock's unique position stems from being the only company with FDA-approved implantable neural arrays for clinical use, a significant regulatory moat that has attracted over $120 million in total funding across multiple rounds.
Blackrock Neurotech emerged from the pioneering neural interface research conducted at the University of Utah's Department of Biomedical Engineering:
2008: Company founded as Blackrock Microsystems, commercializing Utah Array technology developed by Professor Richard Normann's laboratory.
2010: First commercial shipments of Utah Array to research institutions worldwide, establishing the technology as the gold standard for chronic neural recordings.
2012: Launch of Cerebus Neural Signal Processing System, providing integrated data acquisition and signal processing for research applications.
2013: Landmark publication in Lancet demonstrating 7 degrees of freedom control of a robotic arm using Utah Array, validating clinical potential.
2015: Received FDA Investigational Device Exemption (IDE) for first human clinical trial of Utah Array in patients with paralysis.
2016: Established BrainGate2 consortium partnership, providing neural interface technology for groundbreaking clinical research at Massachusetts General Hospital, Brown University, and Stanford University.
2019: MoveAgain BCI system received FDA Breakthrough Device Designation, accelerating regulatory pathway for commercial approval.
2020: Completed first human clinical trial demonstrating safety and efficacy of Utah Array for long-term neural recording in patients with tetraplegia.
2021: Rebranded to Blackrock Neurotech; raised $30M Series B funding led by new investors.
2022: FDA approval of Utah Array for clinical neural recording — first and only FDA-approved implantable neural array.
2023: FDA approval of MoveAgain BCI system for commercial clinical use, marking transition from commercial to clinical stage.
2024: Announced development of Neuralace — next-generation ultra-high-density (10,000+ electrode) array with wireless capabilities.
Blackrock generates revenue through multiple channels:
The company occupies a dominant position in the invasive BCI market:
| Metric | Blackrock Position |
|---|---|
| Invasive BCI Market Share | ~70% (estimated) |
| Clinical Implantations | 50+ patients (most of any invasive BCI) |
| FDA Approvals | 2 (Utah Array, MoveAgain BCI) |
| Peer-Reviewed Publications | 200+ using Blackrock technology |
Total Raised: Over $120 million
Funding Rounds:
| Product | Application | Status | Revenue Model |
|---|---|---|---|
| Utah Array | Chronic neural recording | FDA Approved | Direct sales |
| MoveAgain BCI | Motor restoration for paralysis | FDA Approved | Hospital sales |
| Cerebus System | Research data acquisition | Research use | Direct sales |
| Program | Indication | Development Stage | Expected Launch |
|---|---|---|---|
| Neuralace | Ultra-high-density recording | Pre-clinical | 2026-2027 |
| Wireless Utah Array | Fully implantable BCI | Feasibility | 2025-2026 |
| Bidirectional System | Recording + stimulation | Research | 2027+ |
| DBS Optimization | Parkinson's disease | Clinical trials | 2025 |
Amyotrophic Lateral Sclerosis (ALS): Communication devices for patients with locked-in syndrome. Blackrock technology has been used to restore communication in several ALS patients through the BrainGate consortium.
Spinal Cord Injury: Motor restoration for quadriplegia. The MoveAgain BCI enables wireless control of computers and devices for individuals with upper limb paralysis.
Stroke Rehabilitation: Motor function recovery through neural-controlled prosthetic devices and rehabilitation systems.
Parkinson's Disease: Neural monitoring for deep brain stimulation (DBS) optimization. Blackrock arrays provide real-time neural signals that can guide adaptive DBS algorithms.
Alzheimer's Disease: Research applications for neural recording to understand cognitive decline mechanisms and develop responsive neural interfaces.
Epilepsy: Seizure prediction and responsive neurostimulation through chronic neural monitoring.
Depression: Investigational applications for targeted neuromodulation in treatment-resistant depression.
Blackrock maintains deep partnerships with leading research institutions:
BrainGate Consortium: Long-term partnership with Massachusetts General Hospital, Brown University, Stanford University, and multiple VA hospitals for fundamental BCI research.
University of Utah: Continued research collaboration including technology development and clinical validation.
Multiple NIH Grants: Collaboration on BCI development through various National Institute of Neurological Disorders and Stroke (NINDS) programs.
Existing Partnerships:
Partnership Criteria:
The company selectively pursues partnerships that align with core competencies:
| Company | Technology | Key Differentiator |
|---|---|---|
| Neuralink | N1 implant (1,024 electrodes) | Highest channel count, fully wireless |
| Synchron | Stentrode (16 electrodes) | Endovascular approach, less invasive |
| Paradromics | Connexus Array (65,000 electrodes) | Highest density, development stage |
| Cerebras | Wafer-scale engine (not BCI) | Computing for neural data processing |
The global BCI market is projected to reach $7B by 2030, with invasive BCI representing approximately $1.5B. Blackrock's estimated 70% share of the invasive segment positions it as the dominant player in clinical-grade neural interfaces.
While Blackrock is privately held and does not disclose financials, industry estimates suggest:
| Metric | Status |
|---|---|
| Valuation | $300-400M (estimated, 2023) |
| Total Funding | $120M+ |
| Burn Rate | ~$15-20M annually |
| Runway | 3-4 years at current burn |
Blackrock has developed expertise in FDA regulatory navigation:
510(k) Pathway: Used for Utah Array (substantial equivalence to predicate device)
De Novo Pathway: Used for MoveAgain BCI (novel device classification)
Breakthrough Designation: Utilized for accelerated review of MoveAgain
The combination of:
Creates significant barriers to entry for competitors seeking to commercialize invasive BCI technology.
Blackrock maintains an extensive patent portfolio covering:
Marcus Gerhardt (CEO): Co-founder, previously at Medtronic in neuromodulation
Floyd Warsi (CTO): Previously at Second Sight Medical Products
Dr. John Simeral (Chief Science Officer): BrainGate consortium lead, Brown University
Blackrock emphasizes:
The company has approximately 150 employees with plans to grow to 250+ by 2025, focusing on:
Blackrock aims to establish invasive BCI as a standard-of-care treatment for neurological conditions: